Click on these common “myth-conceptions” about COPD and see the real facts behind them
“The majority of patients with COPD use their inhalers correctly.”
“Long-acting maintenance therapy is generally unnecessary for patients with COPD who are already on short-acting therapy.”
“Nebulized maintenance therapy should only be reserved for patients with very severe COPD.”
“Comorbidities never play a significant role in patients’ ability to use their inhaler correctly.”
“Treatment delivery device is not an important factor when choosing therapy for a patient at hospital discharge.”
“When patients’ symptoms aren’t adequately controlled on their current COPD therapy, it’s always best to add an additional therapy to achieve control.”
“Inhalation technique errors do not contribute to hospitalizations.”
This website is paid for and content developed by Mylan Specialty L.P., a Viatris Company, and Theravance Biopharma US, Inc.
VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
The Myth-Understood logo is a trademark of Mylan Specialty L.P., a Viatris Company.
© 2021 Viatris Inc. All Rights Reserved. NON-2020-1996 V2
Click the “Continue” button to learn
more about a prescription nebulized
treatment for COPD.
Are you a healthcare professional?